OTCPK:CHCR

Stock Analysis Report

Executive Summary

Advanzeon Solutions, Inc., through its subsidiary, Pharmacy Value Management Solutions, Inc., administers and operates a sleep apnea program known as SleepMaster Solutions.

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($301K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Advanzeon Solutions's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CHCR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.8%

CHCR

-0.7%

US Healthcare

0.7%

US Market


1 Year Return

441.8%

CHCR

6.8%

US Healthcare

21.1%

US Market

Return vs Industry: CHCR exceeded the US Healthcare industry which returned 6.8% over the past year.

Return vs Market: CHCR exceeded the US Market which returned 21.1% over the past year.


Shareholder returns

CHCRIndustryMarket
7 Day2.8%-0.7%0.7%
30 Day-30.5%4.8%2.3%
90 Day-9.7%15.0%5.0%
1 Year441.8%441.8%8.7%6.8%23.7%21.1%
3 Year358.5%358.5%47.3%40.6%47.0%37.4%
5 Year272.5%272.5%64.0%52.8%65.7%47.5%

Price Volatility Vs. Market

How volatile is Advanzeon Solutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Advanzeon Solutions undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Advanzeon Solutions is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Advanzeon Solutions has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CHCR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Advanzeon Solutions regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Advanzeon Solutions forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanzeon Solutions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CHCR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Advanzeon Solutions's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Advanzeon Solutions performed over the past 5 years?

30.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CHCR is currently unprofitable.

Growing Profit Margin: CHCR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CHCR is unprofitable, but has reduced losses over the past 5 years at a rate of 30.8% per year.

Accelerating Growth: Unable to compare CHCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CHCR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6.2%).


Return on Equity

High ROE: CHCR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Advanzeon Solutions's financial position?


Financial Position Analysis

Short Term Liabilities: CHCR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CHCR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CHCR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CHCR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: CHCR has a low level of unsold assets or inventory.

Debt Coverage by Assets: CHCR has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CHCR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CHCR has less than a year of cash runway if free cash flow continues to reduce at historical rates of -44.5% each year


Next Steps

Dividend

What is Advanzeon Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CHCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CHCR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CHCR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CHCR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CHCR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Advanzeon Solutions's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average management tenure


CEO

Clark Marcus (77yo)

10.6yrs

Tenure

0

Mr. Clark A. Marcus has been the Chief Executive Officer of Advanzeon Solutions, Inc. since September 2010 and has been its Chairman since May 11, 2009. Mr. Marcus has been the Chief Executive Officer of C ...


CEO Compensation Analysis

Compensation vs Market: Clark's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD528.59K).

Compensation vs Earnings: Clark's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.7yrs

Average Tenure

75yo

Average Age

Experienced Management: CHCR's management team is considered experienced (3.7 years average tenure).


Board Age and Tenure

10.6yrs

Average Tenure

72yo

Average Age

Experienced Board: CHCR's board of directors are seasoned and experienced ( 10.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$1,44527 Aug 19
Clark Marcus
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares5,000
Max PriceUS$0.29
BuyUS$1,25012 Aug 19
Clark Marcus
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares5,000
Max PriceUS$0.25
BuyUS$2,00009 Aug 19
Clark Marcus
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares10,000
Max PriceUS$0.20
BuyUS$1,04509 Aug 19
Clark Marcus
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares5,500
Max PriceUS$0.19
BuyUS$3,20007 Aug 19
Clark Marcus
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares15,000
Max PriceUS$0.22
BuyUS$8,33003 Jul 19
Stephen Kreitzer
EntityIndividual
Role
Member of the Board of Directors
Medical Director & Director
Shares17,000
Max PriceUS$0.49
BuyUS$1,09325 Jun 19
Stephen Kreitzer
EntityIndividual
Role
Member of the Board of Directors
Medical Director & Director
Shares9,500
Max PriceUS$0.12
BuyUS$4,20904 Jun 19
Stephen Kreitzer
EntityIndividual
Role
Member of the Board of Directors
Medical Director & Director
Shares61,000
Max PriceUS$0.069
BuyUS$2,40014 Jan 19
Stephen Kreitzer
EntityIndividual
Role
Member of the Board of Directors
Medical Director & Director
Shares40,000
Max PriceUS$0.06

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Clark Marcus (77yo)

    Chairman & CEO

    • Tenure: 10.6yrs
  • James Koenig (72yo)

    Director

    • Tenure: 4.6yrs
  • Arnold Finestone (89yo)

    CFO, President

    • Tenure: 10.9yrs
    • Compensation: US$90.00k
  • Richard Wright

    Senior Vice President of Business Development

    • Tenure: 9.3yrs
  • Robert Siegel

    President of Comprehensive Care Benefits Inc

    • Tenure: 8.9yrs
  • Lisa Smithers

    Vice President and Director of Operations

    • Tenure: 5.2yrs
  • Stephen Kreitzer (73yo)

    Medical Director & Director

    • Tenure: 1.7yrs
  • Philip Pulver

    Communications Director & Chief Consultant for Contract Negotiations

    • Tenure: 2.2yrs
  • Cesar Vallarta

    Senior Vice President of Sales & Marketing

    • Tenure: 1.7yrs
  • Abdul Rauf

    Chief Operating Officer

    • Tenure: 0.6yrs

Board Members

  • Arthur Yeap (63yo)

    Independent Director

    • Tenure: 10.9yrs
    • Compensation: US$30.00k
  • Clark Marcus (77yo)

    Chairman & CEO

    • Tenure: 10.6yrs
  • James Koenig (72yo)

    Director

    • Tenure: 4.6yrs
  • Arnold Finestone (89yo)

    CFO, President

    • Tenure: 10.9yrs
    • Compensation: US$90.00k
  • Sharon Ray (60yo)

    Independent Director

    • Tenure: 10.9yrs
    • Compensation: US$30.00k
  • Mark Heidt (66yo)

    Director

    • Tenure: 5.3yrs
  • Stephen Kreitzer (73yo)

    Medical Director & Director

    • Tenure: 1.7yrs

Company Information

Advanzeon Solutions, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advanzeon Solutions, Inc.
  • Ticker: CHCR
  • Exchange: OTCPK
  • Founded: 1969
  • Industry: Managed Health Care
  • Sector: Healthcare
  • Market Cap: US$21.355m
  • Shares outstanding: 71.66m
  • Website: https://www.advanzeon.com

Number of Employees


Location

  • Advanzeon Solutions, Inc.
  • 2901 West Busch Boulevard
  • Suite 701
  • Tampa
  • Florida
  • 33618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CHCROTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2009

Biography

Advanzeon Solutions, Inc., through its subsidiary, Pharmacy Value Management Solutions, Inc., administers and operates a sleep apnea program known as SleepMaster Solutions. The company was formerly known a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/14 23:35
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.